Tessel Rigter
YOU?
Author Swipe
View article: Exploring Dutch Citizens’ Perspectives, Expectations, and Decision-Making Regarding Health-Related Direct-to-Consumer Genetic Testing
Exploring Dutch Citizens’ Perspectives, Expectations, and Decision-Making Regarding Health-Related Direct-to-Consumer Genetic Testing Open
Introduction: Qualitative insights into European citizens’ beliefs, expectations, attitudes, and factors relevant for decision-making regarding health-related direct-to-consumer genetic testing (DTC-GT) are scarce. Assessment thereof is es…
View article: Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data
Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data Open
When considering the implementation of a pharmacogenetic passport, strategies can be developed to diminish barriers and strengthen facilitators. It is important to focus on data infrastructure, (visibility of) guidelines, clear division of…
View article: The impact of digital health technologies on moral responsibility: a scoping review
The impact of digital health technologies on moral responsibility: a scoping review Open
Recent publications on digital health technologies highlight the importance of 'responsible' use. References to the concept of responsibility are, however, frequently made without providing clear definitions of responsibility, thus leaving…
View article: Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study
Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study Open
Background The online offer of commercial genetic tests, also called direct-to-consumer genetic tests (DTC-GTs), enables citizens to gain insight into their health and disease risk based on their genetic profiles. DTC-GT offers often consi…
View article: Genetic Screening—Emerging Issues
Genetic Screening—Emerging Issues Open
In many countries, some form of genetic screening is offered to all or part of the population, either in the form of well-organized screening programs or in a less formalized way. Screening can be offered at different phases of life, such …
View article: Information Provision Regarding Health-Related Direct-to-Consumer Genetic Testing for Dutch Consumers: An in-Depth Content Analysis of Sellers’ Websites
Information Provision Regarding Health-Related Direct-to-Consumer Genetic Testing for Dutch Consumers: An in-Depth Content Analysis of Sellers’ Websites Open
Background: Previous studies have suggested that information offered by sellers of health-related direct-to-consumer genetic tests (DTC-GTs) is often incomplete, unbalanced, or too difficult to understand. The extent to which this is the c…
View article: Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study (Preprint)
Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study (Preprint) Open
BACKGROUND The online offer of commercial genetic tests, also called direct-to-consumer genetic tests (DTC-GTs), enables citizens to gain insight into their health and disease risk based on their genetic profiles. DTC-GT offers often cons…
View article: Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users
Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users Open
Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical val…
View article: Predictive value of<i>SLCO1B1</i>c.521T>C polymorphism on observed changes in the treatment of 1136 statin-users
Predictive value of<i>SLCO1B1</i>c.521T>C polymorphism on observed changes in the treatment of 1136 statin-users Open
Purpose Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clin…
View article: Dynamics of reproductive genetic technologies: Perspectives of professional stakeholders
Dynamics of reproductive genetic technologies: Perspectives of professional stakeholders Open
Reproductive and genetic medicine are evolving rapidly, and new technologies are already impacting current practices. This includes technologies that can identify a couples’ risk of having a child with a genetic disorder. Responsible imple…
View article: Pursuing Public Health Benefit Within National Genomic Initiatives: Learning From Different Policies
Pursuing Public Health Benefit Within National Genomic Initiatives: Learning From Different Policies Open
Introduction: Population-based genomic research is expected to deliver substantial public health benefits. National genomics initiatives are widespread, with large-scale collection and research of human genomic data. To date, little is kno…
View article: Towards a Responsible Transition to Learning Healthcare Systems in Precision Medicine: Ethical Points to Consider
Towards a Responsible Transition to Learning Healthcare Systems in Precision Medicine: Ethical Points to Consider Open
Learning healthcare systems have recently emerged as a strategy to continuously use experiences and outcomes of clinical care for research purposes in precision medicine. Although it is known that learning healthcare transitions in general…
View article: Clinical genetics and its adjacent regimes
Clinical genetics and its adjacent regimes Open
Clinical genetics is the prime application of genetics in healthcare, providing highly advanced and reliable diagnostics for patients with (mostly rare) disease of genetic origin. Whereas many novel technologies have expanded the genetic t…
View article: Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective
Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective Open
Stakeholders together were able to formulate required actions to achieve true integration of pharmacogenetics in primary care, but no consensus could be achieved on the prioritization of the actions. Coordination of the current independent…
View article: DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice Open
While the evidence for DPD testing was sufficient, only after the update of a National guideline and local consensus meetings the proportion of FP users that were DPD tested pretreatment rose to 87%. The implementation of personalized medi…
View article: Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity
Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity Open
Advances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systemati…
View article: Stakeholder perspectives on the implementation of genetic carrier screening in a changing landscape
Stakeholder perspectives on the implementation of genetic carrier screening in a changing landscape Open
The absence of a collective sense of urgency for genetic carrier screening, a lack of organisational structures, and uncertainty or even disagreement about the responsibilities seem to be important barriers in the implementation of carrier…